SuperGen, citing insufficient data, reported it has withdrawn its FDA marketing approval application for Orathecin, a new drug intended for treatment of pancreatic cancer. An analyst said the company now would have to decide if it is worth the time and expense needed to conduct additional trials of the drug. The firm's CEO said the filing for approval of Orathecin in Europe remains in effect.

Full Story:

Related Summaries